Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
US9617272B2 · kind B2 · utility
19Cited by
0References
43Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 10, 2014 |
| Grant date | Apr 11, 2017 |
| Priority date | — |
| Expiry date | Mar 10, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D235/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Presently provided are inhibitors of IDO and TDO and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase and tryptophan 2,3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.